Carriage of ELAC2 and RNASEL Genes and Risk Factors in Patients With Prostate Cancer in Burkina Faso

---

Résumé

PURPOSE Genetic factors are one of the significant contributors to prostate cancer (PCa) development. The objective of the present study was to analyze the carriage of the C650T (Ser217Leu) and G1621A (Ala541Thr) mutations of the ELAC2 gene and carriage of RNASEL R462Q and D541E mutations of RNASEL gene with the risk factors in prostate cancer patients in Burkina Faso. METHODS This case-control study. PCR combined with restriction fragment length polymorphism (RFLP) was used to characterize the genotypes of the Ser217Leu and Ala541Thr polymorphisms of the ELAC2 gene. Real-time PCR genotyping of R462Q and D541E variants using the TaqMan® allelic discrimination technique was used. The correlations between the different genotypes and risk factors for prostate cancer were investigated. RESULTS There is no association between prostate cancer risk with the Ser217Leu (p = 0.972), Ala541Thr (p = 0.267) and R462Q (OR = 0.60 95% IC, 0.10–3.51 p = 0.686) and D541E (OR = 2.46 95% IC, 0.78–7.80 p = 0.121. Also, the two ELAC2 SNPs did not correlate with clinical stage, prostate-specific antigen (PSA) level at diagnosis, or Gleason score on biopsies. However, we found that 100% of homozygous carriers of the T650 mutation have an A1621 mutation (P≤0.001). Also, there is a statistically significant difference in the distribution of cases according to the PSA rate at diagnosis (p < 0.001). For the Gleason score distribution, only 13.2% of cases have a Gleason score greater than 7. There is a statistically significant difference in the Gleason score distribution of cases (p < 0.001). CONCLUSION These variants, considered in isolation or in combination, are not associated with the risk of prostate cancer.

Mots-clés

Prostate cancer, Genotype, Genotyping, Biology, Single-nucleotide polymorphism, Carriage, Oncology, Internal medicine, Cancer, Genetics, Gene, Medicine, Pathology